Tenosynovial Giant Cell Tumor
📧 Sign up to get email alerts when something new happens for Tenosynovial Giant Cell Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... [Phase 1]
Phase I trial of pexidartinib (TURALIO) in children and young adults with refractory leukemias and solid tumors including NF1-associated ple…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) [Phase 2]
Phase 2 study of Pimicotinib in Japanese participants with Tenosynovial Giant Cell Tumor is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor [Phase 1]
Phase 1 study to assess the safety, tolerability, and pharmacokinetics of ABSK-021 in patients with advanced solid tumors. The study include…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) [Phase 3]
A Phase 3 clinical trial evaluating emactuzumab for Tenosynovial giant cell tumor is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery [Phase 4]
Phase 4 clinical trial evaluating the accuracy of Indocyanine Green fluorescence imaging during surgery for Tenosynovial Giant Cell Tumor; c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor [Phase 1, Phase 2]
Clinical trial update on Vimseltinib (DCC-3014) for advanced tumors and tenosynovial giant cell tumor (pigmented villonodular synovitis), cu…
-
CLINICAL_TRIALS other · 2025-11-05Clinical Trial Update: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
This clinical trial update describes a real-world participant experience study of Vimseltinib for Tenosynovial Giant Cell Tumor, with the st…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A long-term clinical trial is evaluating potential liver toxicity associated with TURALIO (pexidartinib) treatment in patients with Tenosyno…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) [Phase 3]
Phase 3 clinical trial update for Pimicotinib (ABSK021) in Tenosynovial Giant Cell Tumor, including Pigmented Villonodular Synovitis and Gia…
-
FDA approval · 2025-08-27FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) from Daiichi Sankyo Inc. This notice indicates an approved …
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan [Phase 2]
A Phase 2 study in Japan evaluating pexidartinib for tenosynovial giant cell tumor has posted results (as of 2025-03-03); the trial status i…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Study of Vimseltinib for Tenosynovial Giant Cell Tumor [Phase 3]
Phase 3 study of vimseltinib for Tenosynovial Giant Cell Tumor has posted results; the trial is currently not recruiting.
-
FDA approval · 2025-02-14FDA Approved: ROMVIMZA — Original Application (Deciphera Pharmaceuticals, LLC)
The FDA approved ROMVIMZA (vimseltinib) under an Original Application for tenosynovial giant cell tumor, establishing a new treatment option…
-
FDA approval · 2025-01-03FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
This FDA notice documents a supplemental application approval for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc. The …
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib [Phase 4]
A Phase 4 study assessing discontinuation and re-treatment in Tenosynovial Giant Cell Tumor patients previously treated with pexidartinib; t…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: A Comparative Study of the Efficacy of Multimodal Interventions for Tenosynovitis [NA]
A clinical trial update for a study evaluating multimodal interventions for tenosynovial giant cell tumor (TGCT) is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT [Phase 2]
Phase 2 trial evaluating the safety and efficacy of AMB-05X injections in Pigmented Villonodular Synovitis and Tenosynovial Giant Cell Tumor…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee [Phase 2]
A Phase 2 open-label study evaluating intra-articular AMB-05X injections for knee Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synov…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients [Phase 2]
A Phase 2 trial of intravenous AMB-05X in Tenosynovial Giant Cell Tumor (PVNS) was terminated; results have been posted.
-
FDA approval · 2023-11-16FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) filed by Daiichi Sankyo Inc., resulting in updated regulato…
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT [Phase 3]
Phase 3 study evaluating the efficacy and safety of pexidartinib in adults with Tenosynovial Giant Cell Tumor; results were posted in 2023.
-
FDA approval · 2023-04-17FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) by Daiichi Sankyo Inc.
-
FDA approval · 2022-10-14FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) by Daiichi Sankyo Inc. The action pertains to treatment…
-
FDA approval · 2022-10-06FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc., resulting in updated …
-
FDA approval · 2022-07-14FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)
FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) filed by Daiichi Sankyo Inc., enabling changes to the drug'…